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Bladder cancer predominantly affects an older population, a demographic which is 
growing along with the incidence of bladder cancer [1]. It is the 7th most common 
cancer in the UK, 4th most common in males, with in excess of 10,300 diagnoses in 
2011 and 5081 deaths. This disease and its subsequent treatments result in high 
morbidity irrespective of outcome which impacts significantly on the quality of life 
(QoL) of patients and their carers, and has resource implications for healthcare 
systems.  
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Approximately twenty-five per cent of patients present with muscle-invasive bladder 
cancer (MIBC). Open radical cystectomy with urinary diversion or orthotopic neo-
bladder formation (ONF) has been considered to be the standard of care, though 
recent NICE guidance recommends eligible patients are offered radical surgery or 
radical radiotherapy with concurrent radiosensitizer [2]. Neo-adjuvant chemotherapy 
(NAC) is recommended, improving overall survival by approximately 5%.  
About 1500 radical cystectomies are performed annually in England, an increase of 
more than 50% over the last 10 years, and most are for MIBC. Improved surgical 
techniques, enhanced recovery programmes and centralisation [3] have resulted in 
recently improved perioperative outcomes with 90 day mortality reducing from 5.2% 
to 2.1% despite the increase in elderly patients undergoing the procedure. 
Contemporary surgical series have shown 5 year overall, recurrence free and 
cancer-specific survival rates of 57%, 48% and 67%, respectively [4]. 
Complications rates following radical cystectomy  are  relatively frequent in the 
longer term (over 15 years follow-up) with ureteric obstruction reported  in 14%, 
stomal problems in 24%, bowel problems in 24%, UTI’s in 20% and metabolic 
derangement (severe metabolic acidosis in 1%). Renal insufficiency developed in 
27%, although in this elderly, comorbid population it is difficult to determine how 
much of this is attributable to the diversion [5]. Continence rates for ONF are high 
(>95% daytime and 76% nocturnal). In more recent studies, intermittent self-
catheterisation (CISC) was required in a minority of patients (10%), with higher rates 
observed in women [6]. 
 
Recent radiotherapy studies, evaluating concurrent regimes with radio-sensitizers, 
such as chemotherapy or carbogen and nicotinamide, have seen survival outcomes 
improve and equal results from contemporary surgical series [7, 8].  Unfortunately, a 
randomised trial directly comparing surgical and radiotherapy outcomes in this 
disease has not been completed. The CRUK SPARE trial closed early due to poor 
recruitment and it is unlikely that another randomised study will be attempted.  The 
majority of published data comparing outcomes from these two treatment modalities 
is between single centre surgical series and radiotherapy results of multicentre 
randomised controlled trials. Nevertheless, it appears likely that for some patients 
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these two treatment options confer equivalent outcomes with regard to overall 
survival [9].   
Having two definitive treatment options with equivalent survival end points makes 
QoL outcomes and health economics essential factors in treatment decision-making 
for patients, carers and healthcare providers.  
Studies evaluating QoL outcomes following radical radiotherapy for bladder cancer 
are largely limited to small, single centre, retrospective series and some using 
physician reported or unvalidated questionnaires [10-13]. At the time of assessments 
most participants are recurrence-free biasing the information collected.  
Unfortunately comparison between and across published studies is limited by 
disparate methods and tools used to assess QoL outcomes.  Using an unvalidated 
questionnaire with patients treated with either cystectomy or radiotherapy, Caffo 
found, with 59/93 (63%) evaluable questionnaires, QoL was higher with bladder 
preservation due to the absence of a stoma, low incidence of urinary symptoms and 
better sexual functioning [10].  Similar results were reported in a retrospective study 
comparing patients treated with radiotherapy, those treated with radical cystectomy 
and urostomy during the same period and a random general population sample [11]. 
These data showed 74% (43/58) of the radiotherapy group had little or no distressing 
symptoms from the urinary tract and better overall sexual functioning (higher rates of 
sexual intercourse and ability to ejaculate in men) compared to the surgical group. 
Rate of gastrointestinal toxicity was not significantly different between the two 
groups. Notably, the degree to which sexual function is influenced in women is less 
well documented. Perhaps due to some extent because bladder cancer incidence is 
less in women, though in one QoL study women preferred not to answer the 
question [13]. 
Response to radiotherapy is important in determining the impact the treatment has 
on QoL. Lynch et al compared the QoL of patients with a complete tumour response 
following radical radiotherapy to an age and sex matched control group. Patients 
completed the Nottingham health profile and physicians reported urinary symptoms 
utilising the modified bladder symptom score for haematuria, frequency, nocturia, 
urgency, dysuria, incontinence and rectal symptoms [12]. Both the physician 
assessed symptom scores and the patients’ scores from the Nottingham health 
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profile showed those with a complete response to radiotherapy had little change in 
their QoL. Zietman et al published comparable findings for 71 patients who were 
alive and disease-free a median of 6.3 years (range 1.6-14.9) following transurethral 
resection, chemotherapy and radiotherapy for MIBC [13]. They used a QoL 
questionnaire validated for prostate cancer, adapted for the study, and included 
domains for sexual and physical function, global health functional status, and 
measures of body awareness. Urodynamic evaluation was also performed, but only 
31 completed both the QoL questionnaire and urodynamic assessment. Most 
patients had normal bladder function on urodynamic study. However, from the QoL 
questionnaire 6% of patients reported flow symptoms, 15% urgency and 19% control 
problems. Levels of global health related QoL were found to be high despite 11% of 
women using protective pads and 14% of patients reporting distress from bowel 
symptoms. One prospective study has assessed bladder function at baseline and 
then 6-monthly thereafter to 36 months. It found improvement in bladder function 
following chemo-radiation due to primary tumour control and bladder preservation, 
with satisfactory bladder function for all patients according to LENT-SOMA [14]. 
Scores for physical, cognitive, social and emotional functioning, were all high after 
treatment.  The QoL of patients for whom local tumour control has not been achieved 
have not been investigated yet. 
Studies have extensively reported the QoL outcomes following radical surgery for 
bladder cancer , mainly for comparisons between orthotopic neo-bladder and ileal 
conduit. A recent review of 21 studies including 2285 patients concluded that 
patients with an orthotopic neo-bladder had marginally better QoL [15]. Most studies 
were retrospective, none were randomised, and patients with a neo-bladder were 
younger and fitter, potentially biasing results. Two reviews concluded that existing 
studies had not demonstrated superiority for any particular urinary diversion and 
although overall QoL after surgery remained good, further evidence from prospective 
studies were needed using validated disease specific health related QoL instruments 
[16, 17]. QoL after surgery may not be equally as good for women since Gacci et al 
found that women with a urostomy had lower scores for functional and physical 
wellbeing, and higher levels of fatigue and appetite loss compared to those with an 
ONF, though the small (n=37) sample size of the study is limiting [18]. 
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Clearly current comparative data on QoL, psychosocial morbidity, and normal 
functioning are not adequate to fully inform patients with MIBC making treatment 
decisions. Furthermore, on a population basis this information is required to enable 
healthcare providers to commission services appropriately to support these patients. 
This should lead to improved QoL, reduction in avoidable long-term morbidity and 
potential financial savings for healthcare services.  No studies have included 
comparison of health economic outcomes and nor has any of the retrospective work 
included patients for whom local control has failed following radiotherapy and for 
those who have an upfront cystectomy. Gathering information on fear of recurrence 
is also important as this disease has high recurrence rates, and anecdotally patients 
treated for bladder cancer tell us this worry frequently occurs; mixed populations of 
cancer survivors show 39-87% incur some degree of fear of recurrence associated 
with greater symptomatology and poorer QOL [19]. 
In summary, QoL outcomes following treatment for MIBC have not been 
comprehensively studied despite improved treatment outcomes with the routine use 
of neo-adjuvant chemotherapy, radiosensitization with chemotherapy and carbogen 
and nicotinamide. A study of comparative outcomes would assist patients in their 
decision-making process prior to embarking on treatment. Undoubtedly both 
treatments significantly impact QoL and normal day-to-day functioning. Strategies to 
minimise this would reduce distress and improve overall functioning. A recent review 
of Patient-reported outcome measures (PROMS) and survivorship in radiotherapy 
patients highlights the importance of these in improving practice, symptom, 
management and identifying care needs [20].   For healthcare providers an 
evaluation of the overall impact of different treatment modalities is essential to 
enable appropriate commissioning of support services which may mitigate long-term 
morbidity.  Moreover this fits with a key goal of NHS Outcomes Framework policy to 
improve QoL in patients with long-term conditions (Domain 2 of the NHS Outcomes 
Framework [21]) and emerging international efforts to improve quality of cancer 
survivor care and was highlighted in the recent NICE guidance [2]. Planning is 
underway for a prospective non-randomised QoL study using validated patient 
reported outcomes following the radical treatment of MIBC with the involvement of 
members of Fight Bladder Cancer, input from the NCRI Psychosocial Studies group, 
and treating clinicians. 
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